Inhibition of ACK1 delays and overcomes acquired resistance of EGFR mutant NSCLC cells to the third generation EGFR inhibitor, osimertinib-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Inhibition of ACK1 delays and overcomes acquired resistance of EGFR mutant NSCLC cells to the third generation EGFR inhibitor, osimertinib

Published:2020-12 Issue: Volume:150 Page:26-35
ISSN:0169-5002
Container-title:Lung Cancer
language:en
Short-container-title:Lung Cancer

Author:

Gu Jiajia,Qian Luxi,Zhang Guojing,Mahajan Nupam P.,Owonikoko Taofeek K.,Ramalingam Suresh S.,Sun Shi-Yong

Funder

NIH/NCI

Prostate Cancer Foundation

Emory Winship Cancer Institute lung cancer research

Lee Foundation Award

Publisher

Elsevier BV

Subject

Cancer Research,Pulmonary and Respiratory Medicine,Oncology

Reference30 articles.

1. Cancer statistics, 2019;Siegel;CA Cancer J. Clin.,2019

2. ACK1 tyrosine kinase: targeted inhibition to block cancer cell proliferation;Mahajan;Cancer Lett.,2013

3. ACK1/TNK2 tyrosine kinase: molecular signaling and evolving role in cancers;Mahajan;Oncogene,2015

4. Development of novel ACK1/TNK2 inhibitors using a fragment-based approach;Lawrence;J. Med. Chem.,2015

5. ACK1/TNK2 regulates histone H4 Tyr88-phosphorylation and AR gene expression in castration-resistant prostate Cancer;Mahajan;Cancer Cell,2017

Cited by 14 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Non-Receptor Tyrosine Kinases: Their Structure and Mechanistic Role in Tumor Progression and Resistance;Cancers;2024-08-02

2. GINS2 promotes the progression of human HNSCC by altering RRM2 expression;Cancer Biomarkers;2024-07-01

3. The Role of miR-29a and miR-143 on the Anti-apoptotic MCL-1/cIAP-2 Genes Expression in EGFR Mutated Non-small Cell Lung Carcinoma Patients;Biochemical Genetics;2024-02-20

4. Design, Synthesis, and Biological Evaluation of Dual Inhibitors of EGFR^L858R/T790M/ACK1 to Overcome Osimertinib Resistance in Nonsmall Cell Lung Cancers;Journal of Medicinal Chemistry;2024-02-07

5. Research Progress on AKC1 and Its Small Molecule Inhibitors in Tumor Occurrence and Development;Advances in Clinical Medicine;2024

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3